Marktanalyse - Melanoma - Pipeline Review, H2 2016

Global Markets Direct
12.2016
1656 Seiten

 
Typ:
Marktanalyse
Verfüg­barkeit:
verfügbar
Regionen/­Länder:
  • Europa
  • Asien / Pazifik
  • Mittlerer Osten / Afrika
  • Nordamerika / USA
  • Australien
  • Mittel- / Südamerika
Sprache:
Englisch

Bitte wählen Sie ein Lieferformat und klicken Sie unten auf einen Bestellbutton:

PDF-Datei per E-Mail, Single User Price, versandkostenfrei
PDF-Datei per E-Mail, Site License Price**, versandkostenfrei
PDF-Datei per E-Mail, Enterprisewide Price (Global Site License)***, versandkostenfrei


Hinweise: **The report can be shared by users within one office (one geographical location) ***Across Geographical locations (by the purchasing company only)

Melanoma - Pipeline Review, H2 2016


Summary


Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Melanoma — Pipeline Review, H2 2016, provides an overview of the Melanoma (Oncology) pipeline landscape.

Melanoma is a tumor that develops as a result of the malignant transformation of melanocytes. These cells are derived from the neural crest. Melanomas usually occur on the skin but can arise in other locations where neural crest cells migrate, such as in the gastrointestinal tract or brain. It is more common in women than in men. In women, the most common site is the legs and melanomas in men are most common on the back. Unusual moles, sores, lumps, blemishes, markings, or changes in the way an area of the skin looks or feels are sign of melanoma. Treatment includes surgery, radiation and proton therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Melanoma — Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Melanoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Melanoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Melanoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 17, 92, 111, 3, 208, 24 and 2 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical and Discovery stages comprises 2, 14, 10, 62 and 12 molecules, respectively.

Melanoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.


Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Melanoma (Oncology).
- The pipeline guide reviews pipeline therapeutics for Melanoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Melanoma (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Melanoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Melanoma (Oncology)


Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Melanoma (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Melanoma (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents

Table of Contents 2

Introduction 13

Melanoma Overview 14

Therapeutics Development 15

Melanoma - Therapeutics under Development by Companies 17

Melanoma - Therapeutics under Investigation by Universities/Institutes 38

Melanoma - Pipeline Products Glance 43

Melanoma - Products under Development by Companies 47

Melanoma - Products under Investigation by Universities/Institutes 76

Melanoma - Companies Involved in Therapeutics Development 82

Melanoma - Therapeutics Assessment 338

Drug Profiles 391

Melanoma - Dormant Projects 1537

Melanoma - Discontinued Products 1580

Melanoma - Product Development Milestones 1585

Appendix 1598





List of Tables

Number of Products under Development for Melanoma, H2 2016 72

Number of Products under Development for Melanoma - Comparative Analysis, H2 2016 73

Number of Products under Development by Companies, H2 2016 74

Number of Products under Development by Companies, H2 2016 (Contd..1) 75

Number of Products under Development by Companies, H2 2016 (Contd..2) 76

Number of Products under Development by Companies, H2 2016 (Contd..3) 77

Number of Products under Development by Companies, H2 2016 (Contd..4) 78

Number of Products under Development by Companies, H2 2016 (Contd..5) 79

Number of Products under Development by Companies, H2 2016 (Contd..6) 80

Number of Products under Development by Companies, H2 2016 (Contd..7) 81

Number of Products under Development by Companies, H2 2016 (Contd..8) 82

Number of Products under Development by Companies, H2 2016 (Contd..9) 83

Number of Products under Development by Companies, H2 2016 (Contd..10) 84

Number of Products under Development by Companies, H2 2016 (Contd..11) 85

Number of Products under Development by Companies, H2 2016 (Contd..12) 86

Number of Products under Development by Companies, H2 2016 (Contd..13) 87

Number of Products under Development by Companies, H2 2016 (Contd..14) 88

Number of Products under Development by Companies, H2 2016 (Contd..15) 89

Number of Products under Development by Companies, H2 2016 (Contd..16) 90

Number of Products under Development by Companies, H2 2016 (Contd..17) 91

Number of Products under Development by Companies, H2 2016 (Contd..18) 92

Number of Products under Development by Companies, H2 2016 (Contd..19) 93

Number of Products under Development by Companies, H2 2016 (Contd..20) 94

Number of Products under Investigation by Universities/Institutes, H2 2016 95

Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 96

Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..2) 97

Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..3) 98

Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..4) 99

Comparative Analysis by Late Stage Development, H2 2016 100

Comparative Analysis by Clinical Stage Development, H2 2016 101

Comparative Analysis by Early Stage Development, H2 2016 102

Comparative Analysis by Unknown Stage Development, H2 2016 103

Products under Development by Companies, H2 2016 104

Products under Development by Companies, H2 2016 (Contd..1) 105

Products under Development by Companies, H2 2016 (Contd..2) 106

Products under Development by Companies, H2 2016 (Contd..3) 107

Products under Development by Companies, H2 2016 (Contd..4) 108

Products under Development by Companies, H2 2016 (Contd..5) 109

Products under Development by Companies, H2 2016 (Contd..6) 110

Products under Development by Companies, H2 2016 (Contd..7) 111

Products under Development by Companies, H2 2016 (Contd..8) 112

Products under Development by Companies, H2 2016 (Contd..9) 113

Products under Development by Companies, H2 2016 (Contd..10) 114

Products under Development by Companies, H2 2016 (Contd..11) 115

Products under Development by Companies, H2 2016 (Contd..12) 116

Products under Development by Companies, H2 2016 (Contd..13) 117

Products under Development by Companies, H2 2016 (Contd..14) 118

Products under Development by Companies, H2 2016 (Contd..15) 119

Products under Development by Companies, H2 2016 (Contd..16) 120

Products under Development by Companies, H2 2016 (Contd..17) 121

Products under Development by Companies, H2 2016 (Contd..18) 122

Products under Development by Companies, H2 2016 (Contd..19) 123

Products under Development by Companies, H2 2016 (Contd..20) 124

Products under Development by Companies, H2 2016 (Contd..21) 125

Products under Development by Companies, H2 2016 (Contd..22) 126

Products under Development by Companies, H2 2016 (Contd..23) 127

Products under Development by Companies, H2 2016 (Contd..24) 128

Products under Development by Companies, H2 2016 (Contd..25) 129

Products under Development by Companies, H2 2016 (Contd..26) 130

Products under Development by Companies, H2 2016 (Contd..27) 131

Products under Development by Companies, H2 2016 (Contd..28) 132

Products under Investigation by Universities/Institutes, H2 2016 133

Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 134

Products under Investigation by Universities/Institutes, H2 2016 (Contd..2) 135

Products under Investigation by Universities/Institutes, H2 2016 (Contd..3) 136

Products under Investigation by Universities/Institutes, H2 2016 (Contd..4) 137

Products under Investigation by Universities/Institutes, H2 2016 (Contd..5) 138

Melanoma - Pipeline by 4SC AG, H2 2016 139

Melanoma - Pipeline by AB Science SA, H2 2016 140

Melanoma - Pipeline by AbbVie Inc, H2 2016 141

Melanoma - Pipeline by Abivax SA, H2 2016 142

Melanoma - Pipeline by Acetylon Pharmaceuticals Inc, H2 2016 143

Melanoma - Pipeline by Adamis Pharmaceuticals Corp, H2 2016 144

Melanoma - Pipeline by Adaptimmune Therapeutics Plc, H2 2016 145

Melanoma - Pipeline by Adicet Bio Inc, H2 2016 146

Melanoma - Pipeline by Aduro BioTech Inc, H2 2016 147

Melanoma - Pipeline by Advanced Cancer Therapeutics, H2 2016 148

Melanoma - Pipeline by Advaxis Inc, H2 2016 149

Melanoma - Pipeline by Aeterna Zentaris Inc, H2 2016 150

Melanoma - Pipeline by Affichem SA, H2 2016 151

Melanoma - Pipeline by Agalimmune Ltd, H2 2016 152

Melanoma - Pipeline by Agenus Inc, H2 2016 153

Melanoma - Pipeline by Agilvax Inc, H2 2016 154

Melanoma - Pipeline by AGV Discovery SAS, H2 2016 155

Melanoma - Pipeline by AIMM Therapeutics BV, H2 2016 156

Melanoma - Pipeline by Alethia Biotherapeutics Inc, H2 2016 157

Melanoma - Pipeline by Altor BioScience Corp, H2 2016 158

Melanoma - Pipeline by Amgen Inc, H2 2016 159

Melanoma - Pipeline by Anavex Life Sciences Corp, H2 2016 160

Melanoma - Pipeline by Angimmune LLC, H2 2016 161

Melanoma - Pipeline by Antibe Therapeutics Inc, H2 2016 162

Melanoma - Pipeline by Antigen Express Inc, H2 2016 163

Melanoma - Pipeline by APEIRON Biologics AG, H2 2016 164

Melanoma - Pipeline by Apexigen Inc, H2 2016 165

Melanoma - Pipeline by Aphios Corp, H2 2016 166

Melanoma - Pipeline by APO-T BV, H2 2016 167

Melanoma - Pipeline by Apogenix GmbH, H2 2016 168

Melanoma - Pipeline by Aposense Ltd, H2 2016 169

Melanoma - Pipeline by Aptose Biosciences Inc, H2 2016 170

Melanoma - Pipeline by Arisaph Pharmaceuticals Inc, H2 2016 171

Melanoma - Pipeline by ARMO Biosciences Inc, H2 2016 172

Melanoma - Pipeline by Array BioPharma Inc, H2 2016 173

Melanoma - Pipeline by Asana BioSciences LLC, H2 2016 174

Melanoma - Pipeline by Astellas Pharma Inc, H2 2016 175

Melanoma - Pipeline by Astex Pharmaceuticals Inc, H2 2016 176

Melanoma - Pipeline by AstraZeneca Plc, H2 2016 177

Melanoma - Pipeline by Aurigene Discovery Technologies Ltd, H2 2016 178

Melanoma - Pipeline by Azaya Therapeutics Inc, H2 2016 179

Melanoma - Pipeline by Basilea Pharmaceutica Ltd, H2 2016 180

Melanoma - Pipeline by Batu Biologics Inc, H2 2016 181

Melanoma - Pipeline by Bayer AG, H2 2016 182

Melanoma - Pipeline by BeiGene Ltd, H2 2016 183

Melanoma - Pipeline by Beijing Kawin Technology Share-Holding Co Ltd, H2 2016 184

Melanoma - Pipeline by Bellicum Pharmaceuticals Inc, H2 2016 185

Melanoma - Pipeline by BerGenBio AS, H2 2016 186

Melanoma - Pipeline by Bio-Cancer Treatment International Ltd, H2 2016 187

Melanoma - Pipeline by Biocad, H2 2016 188

Melanoma - Pipeline by Biogazelle NV, H2 2016 189

Melanoma - Pipeline by Biogenomics Ltd, H2 2016 190

Melanoma - Pipeline by BioLineRx Ltd, H2 2016 191

Melanoma - Pipeline by Bioncotech Therapeutics SL, H2 2016 192

Melanoma - Pipeline by Bionomics Ltd, H2 2016 193

Melanoma - Pipeline by BioNTech AG, H2 2016 194

Melanoma - Pipeline by Biothera Pharmaceutical Inc, H2 2016 195

Melanoma - Pipeline by Biovista Inc, H2 2016 196

Melanoma - Pipeline by Boehringer Ingelheim GmbH, H2 2016 197

Melanoma - Pipeline by Boston Biomedical Inc, H2 2016 198

Melanoma - Pipeline by Bristol-Myers Squibb Company, H2 2016 199

Melanoma - Pipeline by Calithera Biosciences Inc, H2 2016 200

Melanoma - Pipeline by Can-Fite BioPharma Ltd, H2 2016 201

Melanoma - Pipeline by CCRP Therapeutics GmbH, H2 2016 202

Melanoma - Pipeline by Cellceutix Corp, H2 2016 203

Melanoma - Pipeline by Celldex Therapeutics Inc, H2 2016 204

Melanoma - Pipeline by Celprogen Inc, H2 2016 205

Melanoma - Pipeline by Celyad SA, H2 2016 206

Melanoma - Pipeline by Checkmate Pharmaceuticals Inc, H2 2016 207

Melanoma - Pipeline by Chipscreen Biosciences Ltd, H2 2016 208

Melanoma - Pipeline by Chugai Pharmaceutical Co Ltd, H2 2016 209

Melanoma - Pipeline by Cipher Pharmaceuticals Inc, H2 2016 210

Melanoma - Pipeline by Cornerstone Pharmaceuticals Inc, H2 2016 211

Melanoma - Pipeline by Cortice Biosciences Inc, H2 2016 212

Melanoma - Pipeline by Corvus Pharmaceuticals Inc, H2 2016 213

Melanoma - Pipeline by CytomX Therapeutics Inc, H2 2016 214

Melanoma - Pipeline by Cytune Pharma SAS, H2 2016 215

Melanoma - Pipeline by CyTuVax BV, H2 2016 216

Melanoma - Pipeline by CZ BioMed Corp, H2 2016 217

Melanoma - Pipeline by Daiichi Sankyo Company Ltd, H2 2016 218

Melanoma - Pipeline by Deciphera Pharmaceuticals LLC, H2 2016 219

Melanoma - Pipeline by DEKK-TEC Inc, H2 2016 220

Melanoma - Pipeline by Dicerna Pharmaceuticals Inc, H2 2016 221

Melanoma - Pipeline by DormaTarg Inc, H2 2016 222

Melanoma - Pipeline by Dynavax Technologies Corp, H2 2016 223

Melanoma - Pipeline by Eisai Co Ltd, H2 2016 224

Melanoma - Pipeline by Eli Lilly and Company, H2 2016 225

Melanoma - Pipeline by Elsalys Biotech SAS, H2 2016 226

Melanoma - Pipeline by Ensol Biosciences Inc, H2 2016 227

Melanoma - Pipeline by EntreChem SL, H2 2016 228

Melanoma - Pipeline by eTheRNA Immunotherapies NV, H2 2016 229

Melanoma - Pipeline by Evelo Therapeutics Inc, H2 2016 230

Melanoma - Pipeline by Exelixis Inc, H2 2016 231

Melanoma - Pipeline by F. Hoffmann-La Roche Ltd, H2 2016 232

Melanoma - Pipeline by Faes Farma SA, H2 2016 233

Melanoma - Pipeline by Five Prime Therapeutics Inc, H2 2016 234

Melanoma - Pipeline by Formune SL, H2 2016 235

Melanoma - Pipeline by Galapagos NV, H2 2016 236

Melanoma - Pipeline by Galectin Therapeutics Inc, H2 2016 237

Melanoma - Pipeline by Genelux Corp, H2 2016 238

Melanoma - Pipeline by Genocea Biosciences Inc, H2 2016 239

Melanoma - Pipeline by Genzyme Corp, H2 2016 240

Melanoma - Pipeline by GlaxoSmithKline Plc, H2 2016 241





List of Figures

Number of Products under Development for Melanoma, H2 2016 72

Number of Products under Development for Melanoma - Comparative Analysis, H2 2016 73

Number of Products under Development by Companies, H2 2016 74

Number of Products under Investigation by Universities/Institutes, H2 2016 95

Comparative Analysis by Late Stage Development, H2 2016 100

Comparative Analysis by Clinical Stage Development, H2 2016 101

Comparative Analysis by Early Stage Products, H2 2016 102

Assessment by Monotherapy Products, H2 2016 395

Assessment by Combination Products, H2 2016 396

Number of Products by Top 10 Targets, H2 2016 397

Number of Products by Stage and Top 10 Targets, H2 2016 397

Number of Products by Top 10 Mechanism of Actions, H2 2016 421

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 421

Number of Products by Top 10 Routes of Administration, H2 2016 444

Number of Products by Stage and Top 10 Routes of Administration, H2 2016 444

Number of Products by Top 10 Molecule Types, H2 2016 446

Number of Products by Stage and Top 10 Molecule Types, H2 2016 446

* Alle Preise sind netto ausgewiesen. In Abhängigkeit von Ihrer Rechnungsanschrift ist hierauf noch USt. zu entrichten (Deutschland z.Z. 19%). Unser Angebot richtet sich ausschließlich an Unternehmen, Gewerbetreibende und Freiberufler.

 

Über marktforschung.de

Branchenwissen an zentraler Stelle bündeln und abrufbar machen – das ist das Hauptanliegen von marktforschung.de. Unser breites Informationsangebot rund um die Marktforschung richtet sich sowohl an Marktforschungsinstitute, Felddienstleister, Panelbetreiber und Herausgeber von Studien, Marktdaten sowie Marktanalysen als auch an deren Kunden aus Industrie, Handel und Dienstleistungsgewerbe.

facebook twitter google plus